АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS
Abstract
the goal of our research was to carry out an analysis of psychotropic drug utilization used for patients with schizophrenia in two (state and municipal) in-patient clinics during 2000 and 2010, using the DDD methodology. As the result, we found out that psychotropic drug utilization increased from 2000 to 2010 in both types of in-patient clinics. Consumption of second-generation antipsychotics increase in state clinic in 2010. And in the state clinic we can observe a favorable trend in the decrease of antidepressants and tranquilizers consumption.
About the Authors
P. S. Nosova
Saratov state medical university named after V.I. Razumovsky
Russian Federation
Russian Federation
O. V. Reshetko
Saratov state medical university named after V.I. Razumovsky
Russian Federation
Russian Federation
References
1. The meeting of representatives of national pharmacovigilance centers participating countries of the WHO International Drug Monitoring. Drug safety and pharmacovigilance. Bezopasnost' lekarstv i farmakonadzor. 2009; 1: 3-6.
2. Tiganov A.S. Endogenous mental illness. [Electronic resource]. Online-Library Mental Health Research Center RAMS [Jendogennye psihicheskie zabolevanija. [Jelektronnyj resurs]. Online-biblioteka Nauchnogo centra psihicheskogo zdorov'ja RAMN]. 2005; http://www. psychiatry.ru/lib/54/book/29.
3. Andretta M., Ciuna A., Corbari L. et al. Impact of regulatory changes on firstand second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 2005; 40: 72-77.
4. Aparasu R.R., Bhatara V., Gupta S. US national trends in the use of antipsychotics. Ann. Clin. Psychiatry. 2005; 17: 147-152.
5. Ayanian J.Z., Weissman J.S., Chasan-Taber S. Quality of care for two common illnesses in teaching and nonteaching hospitals. Health Aff (Millwood). 1998; 17: 194-205.
6. Clinical Guideline 1. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence (NICE). 2002; http:// www.nice.org.uk/cat.asp?c=4.
7. De Oliveira I.R., Juruena M.F. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Therap. 2006; 31: 523-530.
8. Diatta T., Blazejewski S., Portier A. et al. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a crosssectional national survey. Fund. and Clin. Pharmacology. 2007; 21: 371-378.
9. Domino M.E., Swartz M.S. Who are the new users of antipsychotic medications. Psychiatric Services. 2008; 59; 507-514.
10. Duggan M. Do new prescription drug spay for themselves?The case of second-generation antipsychotics. J. Health Economics. 2005; 24: 1-31.
11. Falkai P., Wobrock P., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) psychiatry guidelines for biological treatment of schizophrenia: Part 2. Long-treatment of Schizophrenia. World J. Biol. Psychiatry. 2006; 7: 5-40.
12. Farley J.F., Cline R.R., Schommer J.C. et al. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic therapy. Clin. Ther. 2008; 30: 1524-1539.
13. Gjerden P., Slordal l., Bramness J. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur. J. Clin. Pharmacol. 2010; 66: 911-917.
14. Guidelines for ATC classification and DDD assignment. 2003.
15. Shahian D.M., Liu X., Meyer G.S. Comparing Teaching Versus Nonteaching Hospitals: The Association of Patient Characteristics With Teaching Intensity for Three Common Medical Conditions. Academic Medicine. 2014; 89: 94-106.
16. Trifiro G., Spina E., Brignoli O. et al. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur. J. Clin. Pharmacol. 2005; 61: 47-53.
Review
For citations:
Nosova P.S., Reshetko O.V. АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(4):11-15. (In Russ.)
Views:
977
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 